Upcoming program speakers

Speakers who have been there, done that from both the sponsor and service side attend Outsourced Pharma to openly dialogue with you. In our sessions, authentic discussion between panelists is equaled by the energetic participation of attendees. True story: a panelist described the audience involvement as so boisterous, "it was like they were on the panel!"

Check out the top-shelf line-up.

Speakers by Show Speaker Bios

side background

 

Speakers by Show

San Diego | August 22 - 23, 2017

Confirmed speakers include:
Abzena | George Badescu, VP, Scientific Affairs
Backfield PLLC | Katlin Backfield, Attorney at Law & Consultant (former FDA counsel)
Biogen | Dan Gage, Senior Sup., Technical Dev.
Cortexyme | David Hennings, Sr. Dir., Head, CMC
Crinetics Pharmaceuticals | Ajay Madan, VP., Development
Eli Lilly and Company | Mark Butchko, Sr. Dir., QA, Product Research & Dev.
Elusys Therapeutics | Dennis Knox, Sr. Mgr., Quality
Kura Oncology, Inc. | Xiaohu Deng, Sr. Dir., Head, CMC
Latham Biopharm Group | Susan Dexter, Managing Director
Mirati Therapeutics | Dennis Hester, VP, Product Development & Head, CMC
MabVax Therapeutics | Paul Maffuid, EVP, Research and Dev.
Merck | Rachael Atlee, Regional Dir., ExM Sterile Tech-Ops
Nanomedical Diagnostics, Inc. | Francie Barron, VP, Biology & Regulatory Affairs
Neurocrine Biosciences | Scott Zook, VP, CMC Dev.
NovMetaPharma | Peter Lee, Vice President
Outsourced Pharma | Louis Garguilo, Conference Chair & Chief Editor
Pacira Pharmaceuticals, Inc. | Ray Kaczmarek, VP, Commercial Mfg. & Supply Ops.
Packaging Technologies & Inspection | Oliver Stauffer, CEO
Pfizer | Firelli Alonso, Sr. Dir., Biotherapeutics & Vaccines Outsourcing
Pfizer | Sylvie Sakata, Sr. Dir., External Research Solutions
Pfizer Global Supply | Thomas P. Wilson, VP, Contract Manufacturing Operations
Quality Consulting Associates | Mitchell Rosner, Principal Consultant
Qurient Co. Ltd. | Jaeseung Kim, Sr. Dir., CMC and R&D
Rondaxe | Brian James, SVP, Operations
Rx-360 Data Integrity Group | Barbara Unger, Co-Lead (President, Unger Consulting)
STA Pharmaceutical, A WuXi AppTec Company | Antonio Garrido-Montalban, Executive Dir.
Tioga Research, Inc. | John Newsam, CEO
Tocagen, Inc. | Doug Jolly, EVP., Research & Pharmaceutical Dev.
Vertex Pharmaceuticals | Ben Littler, Sr. Dir., Process Chemistry

 

Past Programs

We're proud of the speakers who've given their time and talent to our programs. Below are just a few of our past participants - bravo!
Achaogen | Tina Larson, VP Technical Operations
ADC Therapeutics | Michael Mulkerrin, VP, Head of CMC
Agensys | Brian Mendelsohn, Leader of ADC Chemistry Group
Allergan | Sesha Neervannan, SVP Pharmaceutical Development
Alnylam Pharmaceuticals | John Frenz, VP Manufacturing
Amunix Operating Inc. | Ulrich Ernst, SVP Manufacturing & Quality Operations
Arcturus Therapeutics | Joseph Payne, President and CEO
BalinBac Therapeutics | John Gregg, President and CEO
Biogen | Thomas Holmes, Sir. Dir. Global External Manufacturing
Capricor Therapeutics | Denise McDade, VP of Quality
Cerulean Pharma | Marc Wolfgang, VP Technical Operations
CytRx | Carrie Helland, VP Project Management and Manufacturing
Depomed | Gerd Kochendoerfer, VP Pharmaceutical Development
Eleven Biotherapeutics | Greg Zarbis-Papastoitsis, VP Process and Manufacturing Sciences
Endocyte | Michael Brinkley, VP Quality
EPRIUS Biopharmaceuticals | Charles Laranjeira, VP Supply Operations
FORMA Therapeutics | Mary Kachinsky, VP Strategic Sourcing & Operations
Genentech | Todd Mabe, Head of External Quality, Biologic Drug Substance
Genzyme | Piet Houwen, Head of External Manufacturing
Innovent Biologics | Claudia Lin, VP Quality
J&J | Courtney Billington, VP Global Pharmaceutical Supply Chain
Medivation | Thomas Templeman, SVP Pharmaceutical Operations
Merck | Bob Kanuga, VP External Manufacturing
Mirati Therapeutics | Dennis Hester, VP Product Development and Head of CMC
Moderna Therapeutics | Hari Pujar, VP Tech Development & Manufacturing
Nektar | Maninder Hora, SVP Pharmaceutical Development and Manufacturing Operations
Neurocrine Biosciences | Scott Zook, Vice President, CMC Development
Orexigen | Philip Roberts, VP Technical Operations
Pernix Therapeutics | Terry Novak, COO
Polynoma | Pat Mallon, COO
Retrophin | Nils Olsson, VP CMC
Revance Therapeutics | Azita Nejad, VP Quality
Shire | Charlene Banard, SVP Quality
Shire | Mani Sundararajan, VP & Head Global Pharmaceutical Technology
Stemline Therapeutics | Joan Connolly, VP Manufacturing
Sorrento Therapeutics | Jeffrey Su, EVP & COO
Sunovion | Vincent Kosewski, VP Supply Chain Operations
Theravance Biopharma | Junning Lee, SVP Technical Operations
Versartis | Patrick Murphy, VP Manufacturing
XenoPort | Sami Karaborni, VP Development Operations

 

Speaker Biographies

Firelli Alonso

Firelli Alonso

Sr. Dir., Biotherapeutics & Vaccines Outsourcing | Pfizer
San Diego | Antibody-Drug Conjugates: ADCs As An Innovation Model For Outsourcing

Dr. Firelli Alonso is Senior Director, External Supply at Pfizer, Inc. She heads the BioTherapeutics and Vaccines Outsourcing group in Worldwide Research and Development. Fi has more than 33 years of combined experience in research, development, and cGMP production of biological products and vaccines, and more than 11 years of experience in outsourcing, project / contract management, and technology transfer to qualified third parties. Her areas of expertise include viral vectors and vaccine development, biotherapeutics and vaccine process development and cGMP production, project management, technology transfer, outsourcing, and budgets and operations. She obtained her Ph.D. in Microbiology from the University of Alabama in Birmingham, followed by postdoctoral research at the U.S. Army Medical Research Institute for Infectious Diseases, Sloan-Kettering Institute for Cancer Research, and Rutgers University Center for Advanced Biotechnology and Medicine. Prior to working for Wyeth / Pfizer in 1996, Fi was at The Salk Institute (Government Services Division), a vaccine contract manufacturer for the U.S. Army.

Rachael Atlee

Rachael Atlee

Regional Director, ExM Sterile Tech-Ops | Merck
San Diego | You Can’t Outsource Data Integrity | The Fast And Slow Of Tech Transfer: Success In The Balance

Biography coming soon.

Katlin Backfield

Katlin Backfield

Attorney at Law & Consultant (former FDA counsel) | Backfield PLCC
San Diego | Regulatory Dynamics For Innovation: Safety First, Please |  You Can’t Outsource Data Integrity

With over 15 years of experience as a pharmaceutical regulatory attorney, including 10 years at the Food and Drug Administration, Katlin McKelvie Backfield uses her extensive expertise to help companies navigate the pre- and post-approval stages of development. Katlin served as Associate Chief Counsel for Drugs with the Office of Chief Counsel at FDA for nine years. She was a regulatory counsel in the Office of Prescription Drug Promotion (OPDP) in the Center for Drug Evaluation and Research at FDA from 2006 to 2008. Prior to joining FDA, Katlin was an associate at Hogan Lovells, LLP, and a law clerk for the Honorable Douglas P. Woodlock of the U.S. District Court for the District of Massachusetts. She graduated cum laude from Georgetown University Law Center in 2001 and received her undergraduate degree from Davidson College. Katlin is a member of the Food and Drug Law Institute's Academic Programs Committee and has served as a speaker for multiple FDLI training programs.

George Badescu

George Badescu

VP, Scientific Affairs | Abzena
San Diego | Antibody-drug conjugates: ADCs as an innovation model for outsourcing

Biography coming soon.

Francie Barron

Francie Barron

VP, Biology & Regulatory Affairs | Nanomedical Diagnostics
San Diego | Regulatory Dynamics for Innovation: Safety First, Please

Spearheading biology research and regulatory affairs at Nanomed, Dr. Barron earned her PhD in Cell Biology, Stem Cells and Development at the University of Colorado Denver Anschutz Medical Campus. Dr. Barron brings 19 years of research experience in academic, pharmaceutical, and regulatory settings to her role optimizing biological systems and directing regulatory strategies for clinical products. At the Ludwig Institute for Cancer Research, Dr. Barron produced over 50 novel antibodies for C. elegans. In her graduate work, Dr. Barron elucidated the signaling pathway by which Hand2 influences lower jaw and tongue development in mice. As a postdoc at Stanford with a NIH training grant award, she worked to develop a new in vitro drug screening process to assess the safety of novel compounds on iPSC-derived human cardiomyocytes. Dr. Barron received an honorable mention in the 2016 Biocom Innovators Under the Age of 40 competition and is excited to bring Nanomed’s clinical products through the FDA to market.

Mark Butchko

Mark Butchko

Sr. Dir., QA, Product Research & Development | Eli Lilly and Company
San Diego | Spotlight Technology: Yes, You Need To Take The Pulse Of Packaging Now

Dr. Butchko is currently Senior Director of Quality Assurance for Eli Lilly and Company in Indianapolis, IN, supporting Lilly’s Product Research & Development organization. Mark has over 17 years of experience in the pharmaceutical industry, joining Lilly in 2000 as a Senior Organic Chemist to develop, optimize, and scale-up manufacturing routes for Lilly’s Active Pharmaceutical Ingredients (API’s). He subsequently served as Manager of Lilly’s Technical Services organization, supporting day-to-day cGMP commercial manufacturing activities in Lafayette, IN. In his current role, Mark provides Quality oversight for internal and external cGMP activities associated with Lilly’s clinical development pipeline and interacts extensively with global collaboration partners and regulatory agencies. He received his Ph.D. in Chemistry from the University of Notre Dame (Notre Dame, IN), and his B.S. Degree in Chemistry from King’s College (Wilkes-Barre, PA).

Xiaohu Deng

Xiaohu Deng

Sr. Dir., Head, CMC | Kura Oncology, Inc.
San Diego | Spotlight Technology: Yes, You Need To Take The Pulse Of Packaging Now

Dr. Deng is Sr. Director, Head of CMC for Kura Oncology. He is responsible for the overall CMC development strategy of Kura’s small molecule, oncology portfolio from preclinical to Phase I, II and beyond. His activities, primarily through external resources, cover API process R&D, formulation development, drug substance and drug product manufacturing, clinical supply and regulatory filing. Prior to joining Kura in 2014, Dr. Deng spent 13 years with Johnson & Johnson, where he focused on process research & development and CRO management. Dr. Deng received BS and MS in Chemistry from Fudan University and Ph.D. in Organic Chemistry from Emory University under the supervision of Dr. Lanny S. Liebeskind. Dr. Deng is a prolific author who has over 60 patents, book chapter, journal publications and abstracts to his credit.

Susan Dexter

Susan Dexter

Managing Director | Latham Biopharm Group
San Diego | Spotlight Technology: Yes, you need to take the pulse of packaging now | New methods for qualifying your service providers, and benchmarking performance

Susan's experience Includes:Broad and deep understanding of drug development, process development and manufacturing of biopharmaceuticals from pre-clinical through commercial; Project Management experience, PMI member; Significant contract negotiations experience, able to evaluate and understand CMO capabilities and identify best fit for outsourcing needs; In depth experience in the use of disposable biomanufacturing technologies; Experience in in-licensing and out-licensing of technologies (gene expression, bioproducts). Susan is interested in providing consultancy services to virtual/small/mid-sized companies needing to outsource biologics process development and manufacturing as well as providing consultancy services to identify the most suitable technologies for development of your pipeline.

Dan Gage

Dan Gage

Sr. Sup.,Technical Dev. | Biogen
San Diego | Is Your CMO Listening: Different Breeds and Different Needs of Sponsor Companies | The Fast And Slow Of Tech Transfer: Success In The Balance

Dan Gage is a pharmaceutical professional with significant technical experience in small and large molecule parenteral formulation development and analytical development. He spent six years at Pfizer Inc. and has been at Biogen for ten. Currently, he is Senior Supervisor at Biogen managing outsourced analytical development. He holds a M.S. in Bioscience Administration from Worcester Polytechnic Institute and a B.S. in Biochemistry from Virginia Tech.

Louis Garguilo

Louis Garguilo

Chief Editor & Conference Chair | Outsourced Pharma
San Diego | Spotlight Leadership Company: Pfizer Global Supply

Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.

Antonio Garrido-Montalban

Antonio Garrido-Montalban

Executive Dir., San Diego Facility Site Head | STA Pharmaceutical, a WuXi AppTec Company
San Diego | The fast and slow of tech transfer: Success in the balance | New methods for qualifying your service providers, and benchmarking performance

Antonio started his chemistry career as a laboratory technician in the than chemical giant Hoechst AG in Frankfurt, Germany. After obtaining his chemical engineering degree from the University of Applied Sciences in Darmstadt, Germany, he moved on to complete an MSc and PhD in Synthetic Organic Chemistry at the University of East Anglia, England, under the direction of Prof. McKillop. Antonio then joined Prof. Barrett’s group at Imperial College London to pursue postdoctoral studies and stayed on as an Assistant Professor before accepting a medicinal chemistry position at the San Diego based biotech company Kemia. More recently, he was the Head of Chemical R&D at Arena Pharmaceuticals and now the Executive Director and Site Head of the STA San Diego site.

David Hennings

David Hennings

Sr. Dir., Head, CMC | Cortexyme
San Diego | Is your CMO listening? Different breeds and different needs of sponsor companies

Dave received his BS in Chemistry from Northeast Missouri State and his Ph.D. in Organic Chemistry from the University of Chicago. After completion of post-doctoral studies at Colorado State University he joined the Process Technology group at Bristol-Myers Squibb in 2000 and later in 2001 he moved to Array BioPharma to join their process chemistry group. At Array he worked on the development of multiple programs in oncology as well as other disease areas such as antibacterial products and pain/inflammation serving in roles ranging from bench scientist, process chemistry lead, group leader and interdisciplinary CMC team leader. In 2015 he helped lead the spin out of the Array CMC group to form Avista Pharma Solutions and was the Head of US Sales for STA from 2106 until April 2017 when he assumed his current role as the Head of CMC for Cortexyme.

Dennis Hester

Dennis Hester

VP, Product Development & Head, CMC | Mirati Therapeutics
San Diego | Regulatory dynamics for innovation: Safety first, please

Dr. Hester was appointed Vice President, Product Development and Head of CMC in July 2014 after building a CMC team and serving as Executive Director, Product Development and Head of CMC from September 2013. Dr. Hester has over twenty years of experience in the development of large and small molecules working with a number of development platforms including solid/liquid oral, inhalation and parenteral technologies. Most recently, he served as Senior Director, Pharmaceutical Sciences at Aragon Pharmaceuticals working on ARN-509, for Prostate Cancer, which was acquired by Johnson & Johnson in July of 2013 and ARN-810, for Breast Cancer, which was acquired by Genentech in July 2014. Prior to Aragon, Dr. Hester was Director, Pharmaceutical Development at Intellikine working on Kinase Inhibitors INK-128 and INK-1117 which were acquired by Takeda in January of 2012. Prior to Intellikine, Dr. Hester held leadership roles in two San Diego startup biotech companies. From March 2003 to October 2006 Dr. Hester was Associate Director, Product Development at Amylin Pharmaceuticals responsible for CMC development activities that ultimately led to the commercialization of Bydureon, a once weekly extended-release parenteral suspension for the treatment of Type 2 diabetes. Prior to Amylin, between December 1999 and March 2003, he was a CMC Lead working on inhalation technologies for various therapeutic indications at Nektar Therapeutics (formerly Inhale Therapeutics). Dr. Hester started his career at Zeneca where he was a product development Scientist/Sr. Scientist from Oct 1992 to August 1999. He holds a Ph.D. degree in Physical Chemistry from the University of Southern California, an ACS Accredited BS degree in Chemistry from the United States Air Force Academy and is an inventor on six U.S. patents.

Brian James

Brian James

SVP, Operations | Rondaxe
San Diego | You Can’t Outsource Data Integrity

Dr. James is a Vice President of Operations and has been with Rondaxe since 2006. Brian oversees project management, API synthesis design and API/Formulation sourcing support to our clients. He manages and oversees projects ranging from pre-IND chemistry development to pre-launch validation and material sourcing for late-stage clinical trials. Prior to joining Rondaxe, he was with Bristol-Myers Squibb for 7 years, where he honed his skills and expertise in API synthesis and sourcing strategies. Brian received both his Ph.D. in Chemistry from University of California, his M.B.A. from Le Moyne College, and performed his post-doctoral fellowship at Colorado State University

Doug Jolly

Doug Jolly

Doug Jolly, Executive VP, Research & Pharmaceutical Development | Tocagen Inc.
San Diego | You can't outsource data integrity

Biography coming soon.

Ray Kaczmarek

Ray Kaczmarek

VP, Commercial Mfg. & Supply Ops. | Pacira Pharmaceuticals, Inc.
San Diego | Spotlight Technology: Yes, you need to take the pulse of packaging now | New methods for your service providers, and benchmarking performance

Biography coming soon.

Jaeseung Kim

Jaeseung Kim

Sr. Dir., CMC and R&D | Qurient Co. Ltd.
San Diego | Is your CMO listening? Different breeds and different needs of sponsor companies

Biography coming soon.

Dennis Knox

Dennis Knox

Sr. Mgr., Quality | Elusys Therapeutics
San Diego | Is Your CMO Listening: Different Breeds and Different Needs of Sponsor Companies

Dennis Knox received his BS in Biology from the University of Rhode Island in 2001. Since then he has worked in the biopharmaceutical industry, holding positions with increasing responsibility at Osteotech, Amgen, Imclone, and Elusys Therapeutics. The past 11 years have been in quality assurance roles. Dennis has served as Sr. Manager of Quality at Elusys Therapeutics, a virtual biotech company located in New Jersey since 2011. Elusys received FDA approval for Anthim® (Obiltoxaximab), a monoclonal antibody that binds the protective antigen (PA) of the Bacillus anthracis toxin, in March of 2016. Dennis has been instrumental in the development of the successful oversight strategy Elusys has applied to multiple contract manufacturing and testing sites.

Peter Lee

Peter Lee

Vice President | NovMetaPharma
San Diego | New methods for qualifying your service providers, and benchmarking performance

- Selection and management of outsourcing partners for drug development (phase-2a in US for type 2 diabetes and obesity) :Tox CRO from Canada, CMOs from US & Canada, API from Switzerland & China - Management of health food registration in China - Selection and management of outsourcing partners for health food products :two CMOs from US - Co-inventor of combo drugs for treating type 2 diabetes (an insulin sensitizer + blood glucose controllers) - License-in of a novel agent for treating type 2 diabetes (a PPAR gamma and alpha dual agonist, an insulin sensitizer) - Management of R&D collaboration projects for drug development for metabolism :with Department of Veterans Affairs, Greater Los Angeles Healthcare System :with POSTECH

Ben Littler

Ben Littler

Sr. Dir., Process Chemistry | Vertex Pharmaceuticals
San Diego | The Fast And Slow Of Tech Transfer: Success In The Balance | Regulatory Dynamics For Innovation: Safety First, Please

Ben Littler received his BA in Chemistry from the University of Oxford and his PhD in Organic Chemistry from the University of Bristol. After completing postdoctoral studies at North Carolina State University he joined the Chemical Development team at AMRI in Albany, NY in 1999. In 2004 Ben joined Vertex Pharmaceuticals in Boston, MA, and since 2005 he has led the Process Chemistry team in San Diego, CA. During his time at Vertex he has worked on over 20 clinical candidate molecules in disease areas including cystic fibrosis, hepatitis C, oncology and pain, at all stages of development ranging from pre-clinical development to Phase 3 manufacture, in roles from bench scientist to global project leader. Ben is currently a Senior Director in the Process Chemistry team, the leader of Vertex’s global cross-functional team to implement continuous manufacturing for small molecule APIs, the author of 14 journal publications and an inventor on 15 patents.

Ajay Madan

Ajay Madan

VP, Development | Crinetics Pharmaceuticals
San Diego | Regulatory dynamics for innovation: Safety first, please

Dr. Madan is vice president of development for Crinetics, where he is responsible for CMC, preclinical, regulatory, and clinical pharmacology. Prior to Crinetics, he was vice president of preclinical development at Neurocrine Biosciences. At Neurocrine, he was responsible for bioanalytical analysis, drug metabolism, pharmacokinetics, toxicology, and clinical pharmacology in support of a number of drug discovery and development programs. He also initiated and led the vesicular monoamine transporter 2 (VMAT2) inhibitor program for the treatment of tardive dyskinesia, resulting in the discovery of a best-in-class compound, valbenazine. Valbenazine demonstrated efficacy and safety in Phase 2 and 3 clinical trials, was awarded fast-track status and breakthrough therapy designation, and was approved by the FDA in 2017. Prior to Neurocrine, he was the chief scientific officer at XenoTech L.L.C., a research company that led the innovation of the current in vitro drug interaction platforms routinely used by all drug discovery and development companies. Dr. Madan is an author of more than 50 scientific publications, and he has been a diplomate of the American Board of Toxicology since 2005. He holds a B.Pharm. degree from Birla Institute of Technology and a Ph.D. in pharmacology and toxicology from the University of Kansas.

Paul Maffuid

Paul Maffuid

EVP, Research & Development | MabVax
San Diego | Antibody-Drug Conjugates: ADCs As An Innovation Model For Outsourcing | Is Your CMO Listening: Different Breeds and Different Needs of Sponsor Companies

Biography coming soon.

John Newsam

John Newsam

CEO | Tioga Research, Inc.
San Diego | The Fast And Slow Of Tech Transfer: Success In The Balance | Is Your CMO Listening: Different Breeds and Different Needs of Sponsor Companies

John M Newsam is CEO of Tioga Research, a CRO that specializes in the research and early development of formulations applied topically. Much of Tioga Research’s global reputation derives from special expertise in formulation innovation (especially leading to patentable compositions) and in performance measurement (with strong capabilities for measuring skin permeation and delivery both by conventional techniques and by high throughput experimentation). John has served in executive roles since 1996. He was CSO of Molecular Simulations Inc. (now Accelrys - from 1996, acquired by Pharmacopeia, Inc. in 1998), Office of the President for hte Aktiengesselschaft (from 2000, acquired by BASF in 2008), CEO of fqubed, Inc. (from 2002, acquired by Nuvo Research in 2005), CEO of Bio4Front, Inc., and Senior VP of Business Development for Nuvo Research, Inc. (from 2009, CA:NRI). John serves as ‘Chemistry Expert’ for the American Chemical Society, and as Chair Elect of the Section on Industrial Science and Technology of the American Association for the Advancement of Science. .

Mitchell Rosner

Mitchell Rosner

Principal Consultant | Quality Consulting Associates
San Diego | Antibody-Drug Conjugates: ADCs As An Innovation Model For Outsourcing

Mitchell H Rosner received his BS in Chemistry from George Washington University (1982) and MS in Toxicology (1985) plus PhD in Pharmacology and Toxicology with a minor in Pharmaceutical Sciences (1989) from the University of Arizona. He began his career as a toxicologist but changed his scope of work to include analytical and process development, formulation development, instrumentation design, technology transfer, validation, quality control and quality assurance. Mitch began his industrial career as an analytical biochemist at IDEC Pharmaceuticals (Biogen) and continued his applied analytical career at CV Therapeutics (Gilead Sciences) and Nektar Therapeutics (Novartis). His roles progressed from Scientist to Senior Director including positions in Quality Control, Analytical Development, and Pharmaceutics. After serving as acting COO at an instrumentation start-up Infrasign, he joined Algenol Biofuels as Senior Director of Analytics and Bioinformatics and at Synthetic Genomics heading Analytical Chemistry and Quality. Mitchell Rosner, PhD is currently Principal Consultant at Quality Consulting Associates.

His work at virtual and start-up companies and large multi-nationals entities has enabled him to provide value-added contributions at all types of organizations. He has contributed to 7 approved products and has multiple patents. These categories of the products have been therapeutic, diagnostic and nutritional supplements. Mitch has held several leadership positions in his career. He is a certified chemist (ACS), project manager (MPM through AAPM), HACCP manager (NEHA) and auditor (CBA and CQA through ASQ).

Sylvie Sakata

Sylvie Sakata

Senior Director, External Research Solutions | Pfizer
San Diego | New Methods For Qualifying Your Service Providers, and Benchmarking Performance

Sylvie Sakata, Senior Director to lead the External Research Solutions based in Pfizer La Jolla in charge of Chemistry, Biology, Reagent Provision, and DMPK services in the pre-clinical sourcing area for many Pfizer Research Units. She focuses efforts on sourcing strategies/operation enablement of file equity, synthesis, analytical chemistry, and new technologies including DNA-encoded libraries.

Sakata’s experience includes: setting up innovative strategies and implementation of different working business models, operations and integrative research, development of IT tools to support external collaborations for Pfizer with Asia/EU/North America partners. This includes working in the area of chemistry technologies, integrated sourcing, API sourcing, analytical services, continuous improvement initiatives, operations/logistical support, risk-mitigation strategies, research informatics solutions to support external research partnerships globally.

She works globally across matrix/multidisciplinary teams and sits on a number of internal leadership teams to support the externalization strategy for Pfizer R&D. She has a number of recognitions in the area of research externalization with expertise in CRO management and set up productive collaborations.

Sakata received her BS in Science with Honors from the University of California Irvine and her PhD from the University of California Irvine. Prior to working for Pfizer La Jolla, Sylvie was at Agouron Pharmaceutical in the chemical research and development, working on the development of the Rhino Virus and HIV NNRTI programs.

Oliver Stauffer

Oliver Stauffer

CEO | Packaging Technologies & Inspection
San Diego | Spotlight Technology: Yes, You Need To Take The Pulse Of Packaging Now

Biography coming soon.

Barbara Unger

Barbara Unger

President | Unger Consulting; Co-Lead | Rx-360 Data Integrity Group
San Diego | You can't outsource data integrity

Barbara formed Unger Consulting, Inc. in December 2014 to provide GMP Quality consulting services to the pharmaceutical and biopharmaceutical industry. My current efforts in auditing and remediation have focused on data integrity / data governance in conjunction with routine GMP auditing. At Amgen, I led the segment of the Corporate GMP Audit group at Amgen focused on API manufacturers, Quality Systems and Computers. I developed, implemented and maintained the GMP Regulatory Intelligence program for 8 years at Amgen Inc. This included surveillance, analysis and communication of GMP related legislation, regulations, guidance and industry compliance enforcement trends. This was an essential service and tool within the Corporate Audit function.

I was the first chairperson of the Rx-360 Monitoring and Reporting work group (2009-2014) that summarized and published summaries of relevant GMP and supply chain related laws, regulations and guidance. I also served as the chairperson of the Midwest Discussion Group GMP-Intelligence sub-group from 2010-2014.

Before Amgen, I worked for the consulting firm of Don Hill and Associates providing regulatory and quality services to the pharmaceutical industry. Prior to that I worked for Eli Lilly and Company in Indianapolis with positions in both the Quality unit and CMC Regulatory Affairs. I began my career in the pharmaceutical / device industry with Hybritech Inc. in San Diego, California.

I received a bachelor's degree in chemistry from the University of Illinois in Urbana, Illinois.

Thomas Wilson

Thomas Wilson

VP, Contract Manufacturing Operations | Pfizer Global Supply
San Diego | Spotlight Leadership Company: Pfizer Global Supply

Tom Wilson is currently the Vice President, CMO Operations, for Pfizer Global Supply (PGS) and Pfizer CentreOne Contract Manufacturing. Tom is a member of the PGS Pharma Ops Leadership Team as well as the CMO Leadership Team in Pfizer Essential Health. Tom is involved in strategic planning, commercial activities as well as manufacturing execution related to the CMO business. Prior to this assignment, Tom was leading the Pfizer Optionality Program for PGS, as well as the Integration Team for Hospira Device Operations. Prior to this, he served as the Operations Leader for the Meridian Medical Technologies remediation program.

Tom has also worked in PGS External Supply leading the Alliance Management team as well as working in PGS Strategy & Transitioning Sites focused on the Diversified Business portfolio. Tom joined Pfizer in 2010 with the acquisition of Wyeth as Vice President, Product Operations, Wyeth Pharmaceutical Operating Unit. He joined Wyeth in 1993 in Rouses Point, New York as Front Line Supervisor, Solid Dose & Liquid Manufacturing, and assumed increasing responsibility in operations and strategy roles. He holds a B.S. in Physics from St. Joseph’s University in Pennsylvania and an M.S.in Administration & Management from St. Michael’s College in Vermont.

Scott Zook

Scott Zook

VP, CMC Development | Neurocrine Biosciences
San Diego | The Fast And Slow Of Tech Transfer: Success In The Balance

Biography coming soon.